Kimi K3.1-Pro

Health systems deploy ambient scribes that draft encounter notes, while evaluations document omissions and fabricated details requiring clinician correction. Signals patient-safety exposure inside routine documentation and tightens requirements for note-level review, audit trails, and error reporting.

Writing · Concrete actor (hospital systems) and event (deploy AI). Lacks specific company/product names, dates, or numbers.

Published evaluations of sepsis and imaging models show accuracy shifts across hospitals, patient subgroups, and deployment periods. Indicates local validation, subgroup testing, and drift monitoring must accompany procurement instead of relying on single-site evidence.

Judge · Multiple peer-reviewed studies demonstrate AI model performance degradation due to data shifts in clinical settings, necessitating continuous monitoring and local validation.

Writing · Concrete actors (hospitals), events (evaluations, accuracy shifts), and actions (validation, monitoring) are present. Lacks specific temporal anchors beyond 'deployment periods'.

US payers reimburse autonomous AI diabetic eye examinations under CPT 92229, separating payment from clinician interpretation. Signals quality programs must track algorithm-only encounters, missed referrals, and demographic performance alongside conventional diagnostic services.

Judge · US payers reimburse autonomous AI diabetic eye exams via CPT 92229. Reimbursement is separate from clinician interpretation. Quality programs track key metrics.

Writing · Concrete actor, event, and code. Active voice. Specific tracking elements. Deduction for 'must track' as a future claim, but anchored.

Health systems pilot large language models for chart summarization, inbox replies, and decision support under clinician review and restricted data access. Signals governance must cover generated advice, source traceability, and escalation criteria beyond conventional device validation.

Judge · Pilots for LLMs in healthcare, including chart summarization and inbox replies under clinician review, are documented. Governance discussions around AI-generated advice and traceability are also underway.

Writing · Concrete actors (health systems), named events (pilots). Lacks specific names, but anchored with processes (governance) and uses active voice.

The EU AI Act classifies medical-device AI requiring third-party conformity assessment as high-risk and phases in provider and deployer obligations. Indicates hospital procurement must map conformity assessments, technical documentation, and role allocation across vendors and internal AI teams.

Judge · The EU AI Act classifies medical devices requiring third-party conformity assessment as high-risk. This necessitates coordinated controls for hospital networks using such AI products.

Writing · Concrete actor, event, and anchor, but lacks a specific product/filing. Contains some generic forecast.

FDA final guidance defines marketing-submission content for predetermined change control plans, including modification protocols and validation methods for AI-enabled devices. Indicates procurement can assess update protocols, retraining triggers, and evidence commitments instead of treating clearance as a fixed-product decision.

Judge · FDA's December 2024 final guidance details PCCPs for AI-enabled device software, requiring evidence and approval for model updates. This will impact manufacturers and health systems.

Writing · Names FDA, concrete output (final guidance), and specific content (modification protocols). Strong active voice.

ONC's HTI-1 rule requires certified health IT developers to disclose source attributes and risk-management practices for predictive decision support interventions. Indicates hospitals need inventory-level evidence on training data, validation, fairness, and monitoring for embedded EHR models.

Judge · The ONC HTI-1 rule mandates transparency for predictive decision support interventions (DSI) in certified health IT, effective January 1, 2025. This allows hospitals to access more algorithm information.

Writing · Names ONC and HTI-1 rule, details 'transparency and risk-management requirements,' and 'model documentation, evaluation evidence, and risk-management information.' Strong specifics. Present tense.

California's SB 1120 requires licensed clinicians to review utilization-management decisions when health plans use AI, algorithms, or software tools. Indicates network utilization teams need documented human judgment, appeal records, and vendor controls across prior-authorization workflows.

Judge · California's SB 1120 specifically mandates human clinical review for AI-driven utilization management decisions, prohibiting AI from denying or modifying care based on medical necessity.

Writing · Concrete actor (California), event (SB 1120), and measurable shift (human review for AI decisions). Good use of active voice.

Health systems establish enterprise AI inventories and review boards covering clinical, administrative, and employee-built tools, including models embedded in vendor products. Indicates strategy teams need accountable ownership, intake thresholds, and decommissioning criteria across the full model lifecycle.

Judge · Hospitals are implementing comprehensive AI governance frameworks, including inventories and review boards for various AI tools. This encompasses clinical, administrative, and vendor-embedded models, emphasizing lifecycle management and accountability.

Writing · Concrete actor (health systems), event (establish inventories), but lacking specific quantitative/temporal anchor. 'Indicates' weakens objective tone.

Health systems add AI-specific procurement terms covering validation data, update notices, cybersecurity, audit access, indemnity, and model retirement. Indicates contracts now function as operational safety controls, making vendor lock-in and undocumented model changes enterprise risks.

Judge · Multiple sources detail that health systems are implementing AI-specific contractual terms to manage risks associated with AI adoption, including model changes, cybersecurity, and liability. [healthsectorcouncil.org](https://healthsectorcouncil.org/wp-content/uploads/2026/04/AI-Third-Party-Risk-Guide.pdf), [mosaiclifetech.com](https://mosaiclifetec

Writing · Concrete actor (health systems), named events (procurement terms, updates). Lacks a specific quantitative or temporal anchor.

OpenAI and cloud providers publish model deprecation dates, while hospitals embed specific releases in documentation and administrative workflows. Indicates operations need version inventories, regression tests, and cutover plans comparable to clinical system upgrades.

Judge · OpenAI and Microsoft publish model deprecation dates and support policies, indicating the need for detailed migration planning, including inventories and regression testing, akin to clinical system upgrades.

Writing · Concrete actors (OpenAI, cloud providers, hospitals) and events (model deprecation, embedding releases) are named. Active voice and present tense are used. Lacks a specific quantitative or temporal anchor for the deprecation dates.

Hospitals extend downtime and cybersecurity exercises to AI failures, including corrupted outputs, unavailable model endpoints, and vendor rollback. Indicates operational resilience depends on manual fallbacks, output quarantine, escalation ownership, and recovery testing.

Judge · Hospitals are actively developing and implementing AI incident response protocols, extending existing cybersecurity and downtime planning.

Writing · Names actors (hospitals, vendors), events (downtime, exercises, failures), and concrete actions. Lacks strong quantifiers/temporal anchors.

US health systems using ambient documentation add verbal consent scripts, signage, and opt-out workflows for recorded clinical encounters. Signals trust depends on consistent disclosure, recording retention rules, and practical options for declining AI-assisted visits.

Judge · Health systems use ambient AI documentation with varied consent processes. Patient understanding of recording and data use is crucial. Opt-out options exist but consistency varies.

Writing · No concrete actor, event, or specific anchor. 'Varying by site' is vague. Active voice is good.

Health systems test disclosures on AI-drafted portal replies and maintain clinician approval before patients receive messages. Signals transparency policies must distinguish drafting assistance from autonomous communication and preserve accessible human review.

Judge · California law (AB 3030) effective Jan 1, 2025, requires AI disclosure for patient clinical info. The signal correctly identifies a regulatory shift and the implication of transparency.

Writing · Names specific states and an action (disclosure). Lacks a concrete actor or temporal anchor. "Baseline patient expectation" is a generic forecast.

HHS Section 1557 rules require covered organizations to identify patient-care decision support tools and address discrimination risks. Signals patient trust work needs subgroup testing, accessible explanations, and remediation channels linked to compliance programs.

Judge · HHS Section 1557 final rule mandates covered entities to identify and mitigate discrimination risks in patient-care decision support tools. This includes subgroup testing and remediation.

Writing · Concrete actor (HHS, organizations) and event (Section 1557 rules). Lacks quantitative/temporal anchor for full specificity.

The European Health Data Space establishes secondary-use rules and opt-out mechanisms, while US health AI training relies on varied HIPAA permissions and contracts. Indicates trust programs need plain-language data-use notices and auditable consent choices across care, research, and vendor relationships.

Judge · EHDS mandates clear opt-out for secondary use. US relies on HIPAA, BAA, and contracts for training rights. Both need transparent data use and consent.

Writing · No concrete actor, event, or quantifiers. Uses active voice for a general observation.